Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 101

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 101
---
 New Semnur Board determines to pay to its executive and non–executive directors. |

| • |     | Our Initial Shareholders, members of our management team or their respective affiliates, may receive                                                                                                                                                                  
 reimbursement for any out–of–pocket expenses incurred by them in connection with activities conducted on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and                             
 business combinations as well as traveling to and from the offices or similar locations of prospective target businesses, including Semnur, to examine their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us in this regard. |

| • |     | Denali’s officers, advisors and directors are not required to, and will not, commit their full time to                                                                                                                                       
 Denali’s affairs, which may result in a conflict of interest in allocating their time between Denali’s operations and the proposed Business Combination, on one hand, and their other businesses, on the other hand. In addition, certain of 
 Denali’s officers and directors presently have, and any of them in the future may have additional, fiduciary and contractual duties to other entities, and therefore could have                                                              |

48

| conflicts of interest in determining whether to present such business combination opportunity to such entity, subject to their fiduciary duties under Cayman Islands law. Denali does not believe 
 that such duties have had any material impact on the identification of companies that may be appropriate acquisition targets.                                                                     |

| • |     | At the option of the Sponsor, the $1,408,200 and $115,037 principal balances as of March 31, 2025 under the                                                                                                                                   
 Sponsor Convertible Promissory Note and Sponsor Extension Convertible Promissory Note, respectively, may be converted into Denali Private Placement Shares, at the price of $10.00 per Denali Private Placement Share, in connection with the 
 consummation of an initial business combination.                                                                                                                                                                                              |

| • |     | Denali may be entitled to distribute or pay over funds held by Denali outside the Trust Account to the Sponsor or 
 any of its affiliates prior to the closing of the Business Combination.                                           |

| • |     | The directors and officers of Denali own the number of Class B Ordinary Shares as shown below. |

| Name of Person      |     | Position                             |     | Founder Shares |
| Lei Huang           |     | Chief Executive Officer and Director |     |         50